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Inhibition of SHP2-mediated dephosphorylation
of Ras suppresses oncogenesis
Severa Bunda1, Kelly Burrell2, Pardeep Heir1, Lifan Zeng3, Amir Alamsahebpour2, Yoshihito Kano1,4,
Brian Raught5, Zhong-Yin Zhang3, Gelareh Zadeh2 & Michael Ohh1,4
Ras is phosphorylated on a conserved tyrosine at position 32 within the switch I region via Src
kinase. This phosphorylation inhibits the binding of effector Raf while promoting the
engagement of GTPase-activating protein (GAP) and GTP hydrolysis. Here we identify
SHP2 as the ubiquitously expressed tyrosine phosphatase that preferentially binds to and
dephosphorylates Ras to increase its association with Raf and activate downstream
proliferative Ras/ERK/MAPK signalling. In comparison to normal astrocytes, SHP2 activity is
elevated in astrocytes isolated from glioblastoma multiforme (GBM)-prone H-Ras(12V)
knock-in mice as well as in glioma cell lines and patient-derived GBM specimens exhibiting
hyperactive Ras. Pharmacologic inhibition of SHP2 activity attenuates cell proliferation,
soft-agar colony formation and orthotopic GBM growth in NOD/SCID mice and decelerates
the progression of low-grade astrocytoma to GBM in a spontaneous transgenic glioma mouse
model. These results identify SHP2 as a direct activator of Ras and a potential therapeutic
target for cancers driven by a previously ‘undruggable’ oncogenic or hyperactive Ras.
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T
he three human Ras genes (HRas, NRas and KRas) are the
most commonly mutated oncogenes in cancer. They
encode highly related 188–189 amino-acid proteins that
are membrane-bound GTP/GDP-binding proteins, which serve
as a ‘molecular switch’ linking receptor and non-receptor tyrosine
kinase activation to downstream cytoplasmic and nuclear
signalling events involved in a wide range of biological processes
such as cell proliferation, differentiation and apoptosis1–5.
Ras cycles between the inactive GDP- and the active
GTP-bound states6. Ras is turned ‘ON’ by the exchange of GDP
with GTP, catalysed by guanine-nucleotide exchange factors7.
GTP-bound Ras has high afﬁnity for effector molecules such as
Raf, which activates the cell proliferative mitogen-activated
protein kinase (MAPK) pathway8. Ras is subsequently turned
‘OFF’ upon the hydrolysis of the bound GTP to GDP via its
intrinsic GTPase activity, which is accelerated by GTPase-
activating proteins (GAPs)9. Cancer-associated mutations in Ras,
frequently in condons 12, 13 and 61, convert Ras into an active
oncoprotein by impairing its GTPase activity10. Other
components of the Ras signalling pathway have also been found
to be altered in many cancers, which inappropriately activate the
otherwise ‘normal’ Ras to trigger various downstream signalling
pathways11. For example, loss of or mutation in neuroﬁbromin 1
(NF1 that encodes GAP) in neuroﬁbromatosis type 1 (ref. 12),
mutation in SHP2 (also known as PTPN11 that encodes protein
tyrosine phosphatase) in juvenile myelomonocytic leukaemia13,
and the overexpression of growth factor receptors in breast
cancer14 and glioblastoma multiforme (GBM)15 have been
associated with the hyperactivation of wild-type (WT) Ras.
GBM is the most common and most aggressive malignant
brain tumour in humans. GBMs are classiﬁed as either primary or
secondary GBM16. Primary GBM, which comprises B90% of all
GBMs, develops rapidly de novo, whereas secondary GBM
progresses from a low-grade astrocytoma to a high-grade
glioma through the acquisition of additional genetic
alterations17. In both cases, hyperactive receptor tyrosine
kinases, epidermal growth factor receptor (EGFR) and platelet-
derived growth factor receptor (PDGFR) potentiate common
downstream Ras and phosphatidylinositol 3-kinase/Akt pathways
to drive tumour growth and survival18,19. Thus, although
mutations in Ras are rare in GBM, elevated levels of activated
Ras are prevalently observed in GBM.
The ubiquitous tyrosine phosphatase SHP2 has emerged as a
major regulator of the Ras/MAPK signalling pathway20. Germline-
activating mutations in SHP2 cause Noonan syndrome, whereas
somatic gain of function SHP2 mutations have been identiﬁed
in several haematologic malignancies, most notably juvenile
myelomonocytic leukaemia. However, the molecular mechanism
by which SHP2 precisely activates the Ras/MAPK pathway remains
unclear. Recently, we showed that Src-mediated phosphorylation of
Ras promotes Raf displacement from Ras while enhancing GAP
recruitment and subsequent GTP hydrolysis, thereby inactivating
Ras21. Here, we show that SHP2 preferentially binds to and
dephosphorylates tyrosyl phosphorylated Ras; an event that is
required for the (re)activation of Ras and the continuation of Ras
GTPase cycle. Notably, molecular or pharmacologic SHP2
inhibition attenuated the Ras activation and downstream MAPK
signalling, and suppressed the progression of tumours in mouse
models of GBM. We thus show that SHP2 is a direct activator of
Ras and a potential therapeutic target for cancers driven by a
previously ‘undruggable’ oncogenic or hyperactive Ras.
Results
SHP2 dephosphorylates tyrosyl-phosphorylated Ras. Recently,
we showed that Src phosphorylates Ras on tyrosine 32 within the
switch I region, which decreased the association between Raf and
Ras while enhancing the binding of GAP to Ras to promote
GTP hydrolysis and the inactivation of Ras21. Treatment of
HEK293 cells co-expressing HA-N-Ras(WT or 12D) and
c-Src with a general protein phosphotyrosine phosphatase
inhibitor (sodium orthovanadate) increased the level of tyrosyl
phosphorylated N-Ras(WT or 12D). By comparison, treatment
with a serine/threonine phosphatase inhibitor calyculin A did not
result in increased tyrosyl-phosphorylated N-Ras(WT) (Fig. 1a),
suggesting that a tyrosine phosphatase actively dephosphorylates
Ras.
Considering that a protein tyrosine phosphatase SHP2 has a
pivotal role in the activation of the Ras/MAPK pathway22, we
asked whether SHP2 is involved in the dephosphorylation of
tyrosyl phosphorylated Ras. Pharmacologic inhibition of SHP2
using a speciﬁc cell-permeable SHP2 inhibitor, II-B08 (ref. 23),
increased tyrosyl phosphorylated HA-N-Ras(WT) level in a dose-
dependent manner (Fig. 1b). Treatment with another SHP2
inhibitor, PHPs1, or ectopic expression of two independent and
highly speciﬁc and blocking SHP2 monobodies (NSa1 and NSa5
ref. 24), likewise increased HA-N-Ras(WT) phosphorylation in
the presence of c-Src (Supplementary Fig. 1a and Fig. 1c,
respectively). This effect was speciﬁc as it was not observed with
the use of the V33R non-blocking control antibody. However,
pharmacologic inhibition of another non-receptor phospho-
tyrosine protein phosphatase, protein tyrosine phosphatase 1B
had a negligible effect on HA-N-Ras(WT) phosphorylation
(Supplementary Fig. 1b). Moreover, unlike WT SHP2, which
attenuated HA-N-Ras(WT or 12D) tyrosyl phosphorylation in
the presence of c-Src (Fig. 1d and Supplementary Fig. 1c), a
catalytically dead SHP2(C459S) dominant-negative mutant allele
or short hairpin RNA-mediated knockdown of endogenous SHP2
increased the level of tyrosyl phosphorylated HA-N-Ras(WT or
12D; Fig. 1d,e and Supplementary Fig. 1d). Notably, tyrosyl
phosphorylation of HA-N-Ras was not observed in the presence
of catalytically dead c-Src(K295R Y527F) mutant irrespective
of the expression of WT or dominant-negative SHP2
(Fig. 1e). Recombinant GST-SHP2 dephosphorylated tyrosyl-
phosphorylated recombinant GST-H-Ras(WT) in the presence of
recombinant c-Src following an in vitro kinase assay (Fig. 1f).
These results support the notion that SHP2 dephosphorylates
c-Src-induced tyrosyl-phosphorylated Ras.
SHP2 and Ras activities are elevated in GBM. Oncogenic HA-
H-Ras(12V) knock-in RasB8 mice are prone to GBM25.
Interestingly, astrocytes derived from newborn pups (RasB8p0)
that are tumour free had markedly lower level of phosphorylated
SHP2, which correlated with less SHP2 activity, compared
with astrocytes derived from 3-month-old mice (RasB8p3) with
GBM (Fig. 2a). Consistent with this observation, HA-H-Ras(12V)
in RasB8p3 astrocytes had increased binding to Raf:RBD
(Ras-binding domain) compared with RasB8p0 astrocytes
(Supplementary Fig. 2a). Pharmacologic inhibition of the
elevated SHP2 activity in RasB8p3 astrocytes using II-B08 or
PHPs1 augmented epidermal growth factor (EGF)-induced
tyrosyl phosphorylation of HA-H-Ras(12V) without affecting
EGF-induced increase in Src phosphorylation, and attenuated
the binding of Raf:RBD to HA-H-Ras(12V) (Fig. 2b and
Supplementary Fig. 2b–d). These results suggest that the
heightened SHP2 activity promotes oncogenic Ras(12V)
dephosphorylation and activity in RasB8p3 astrocytes.
GBM cell line U87 harbours a hyperactive, but otherwise WT,
Ras that is predominantly in the active GTP-bound form unlike
normal human astrocytes (NHA), which harbour Ras that is
predominantly in an inactive GDP-bound state15. U87-viii
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astrocytes associated with aggressive glioma cell proliferation
express in addition a hyperactive EGFR variant III. SHP2 activity
and phosphorylation level were signiﬁcantly higher in U87-viii
compared with U87 cells, which in turn show elevated SHP2
activity compared with NHA (Fig. 2c). II-B08 treatment of U87
cells attenuated SHP2 activity and markedly increased tyrosyl
phosphorylation of Ras, which was abrogated in the presence of
lambda phosphatase (Fig. 2d and Supplementary Fig. 2e,f).
Notably, the enhanced tyrosyl phosphorylation of endogenous
Ras observed in U87 and U87-viii astrocytes post-EGF and II-B08
treatment correlated with enhanced Src activity, which was
markedly attenuated in the presence of Src kinase inhibitor PP2
(Fig. 2e and Supplementary Fig. 3a,b). These results further
support the notion that SHP2 actively dephosphorylates Src-
induced tyrosyl phosphorylated Ras.
We next examined SHP2 and Ras activity status in human
primary GBM tumours, grade II gliomas and normal brain tissue,
using tissue extracts assayed in a Raf-RBD buffer. GBM tumours
showed the greatest elevation of Raf:RBD binding to Ras, whereas
low-grade gliomas showed modest increase in Raf:RBD binding
to Ras in comparison to normal brain tissue, which showed
negligible binding of Ras to Raf:RBD (Fig. 2f). Notably, GBM
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Figure 1 | Tyrosine phosphatase SHP2 dephosphorylates wild-type and oncogenic Ras. (a) HEK293 cells transfected with the indicated plasmids were
treated with the indicated inhibitors, lysed, immunoprecipitated with anti-HA antibody and immunoblotted with the indicated antibodies. (b) HEK293 cells
transfected with the indicated plasmids were treated with increasing concentrations of II-B08, lysed, immunoprecipitated with anti-HA antibody and
immunoblotted with the indicated antibodies. (c) HEK293 cells transfected with the indicated combination of plasmids and monobodies were lysed,
immunoprecipitated with anti-HA antibody and immunoblotted with the indicated antibodies. (d,e) HEK293 cells transfected with the indicated plasmids
were lysed, immunoprecipitated with anti-HA antibody and immunoblotted with the indicated antibodies. (f) Bacterially puriﬁed recombinant human
GST-H-Ras(WT) was subjected to in vitro kinase assay in the presence of bacterially puriﬁed recombinant human active Src kinase. Subsequent
dephosphorylation reaction was conducted using increasing amounts of bacterially puriﬁed recombinant human active GST-SHP2 followed by
immunoprecipitation (IP) with anti-Ras antibody and immunoblotted with the indicated antibodies. The immunoblot data are representative of at least
three separate experiments. WCE, whole-cell extract.
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Figure 2 | SHP2 and Ras activities are elevated in mouse and human GBM cell lines and primary patient-derived GBM specimen. (a) RasB8p0 or p3
astrocytes expressing the HA-H-Ras(12V) transgene derived from GBM-prone mice were either lysed and immunoblotted with the indicated antibodies
(top panel) or subjected to SHP2 activity assay (bottom panel). Data represent mean±s.e.m. of three independent experiments performed in triplicate.
*Po0.05 Student’s t-test compared with RasB8p0. (b) RasB8p3 astrocytes were serum starved and pretreated with (þ ) or without ( ) II-B08 followed
by treatment with (þ ) or without ( ) 1 ngml 1 of EGF. Equal amounts of lysates were immunoprecipitated with anti-HA antibody and immunoblotted
with the indicated antibodies. (c) Normal human astrocytes (NHA), U87 human GBM astrocytes or U87 astrocytes stably expressing EGFRviii deletion
mutant (U87-viii) were either lysed and immunoblotted with the indicated antibodies (top panel) or subjected to SHP2 activity assay (bottom panel). Data
represent mean±s.e.m. of three independent experiments performed in triplicate. *Po0.05 Student’s t-test compared with NHA. (d) U87 astrocytes were
treated with (þ ) or without ( ) lambda phosphatase (l PPase), II-B08 or sodium orthovanadate (Na3V04) were lysed, immunoprecipitated with anti-Ras
antibody and immunoblotted with indicated antibodies. (e) U87 astrocytes were serum starved and pretreated with (þ ) or without ( ) PP2 or II-B08 and
treated with (þ ) or without ( ) 1 ngml 1 of EGF, lysed, immunoprecipitated with anti-Ras antibody and immunoblotted with the indicated antibodies.
(f) Patient-derived GBM or grade II astrocytoma samples were lysed pulled down using Raf:RBD beads, and immunoblotted with indicated antibodies. The
immunoblot data are representative of at least three separate experiments. IP, immunoprecipitation; WCE, whole-cell extract.
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tumours displayed markedly increased level of phosphorylated
SHP2 and ERK followed by grade II gliomas in comparison to
normal counterparts (Fig. 2f and Supplementary Fig. 4a).
Elevated SHP2 phosphorylation status was also evident in four
additional human GBM cell lines, U251, U118, A172 and T98G
(Supplementary Fig. 4b), and SHP2 inhibition attenuated
phosphorylated ERK and AKT levels in two different glioma
stem cell (GSC) neurosphere cultures derived from ﬂeshly
operated tumour samples from GBM patients (Supplementary
Fig. 4c). These results are consistent with the elevated SHP2 and
Ras/pERK activity status observed in astrocytes derived from
GBM-prone mice.
Src-mediated phosphorylation of Ras promotes SHP2 binding.
We asked whether c-Src mediated tyrosyl phosphorylation of Ras
promoted SHP2 binding to Ras. Ectopically expressed HA-N-
Ras(WT) co-precipitated with Flag-SHP2 and Src (Fig. 3a).
Importantly, HA-N-Ras(WT) binding to Flag-SHP2 markedly
increased when co-expressed with c-Src, but not in the presence of
kinase-dead c-Src(K295R Y527F) (Fig. 3a and Supplementary
Fig. 3c). In comparison to Flag-N-Ras(WT), Flag-N-Ras(Y32F)
mutant that escapes tyrosyl phosphorylation by c-Src bound
considerably less to Flag-SHP2(WT) (Supplementary Fig. 3d).
These results suggest that c-Src-mediated phosphorylation of
N-Ras promotes SHP2 recruitment to tyrosyl phosphorylated
N-Ras. In support of this notion, endogenous Ras bound to SHP2
in WT mouse embryonic ﬁbroblasts (MEFs), which was increased
upon EGF treatment, but markedly attenuated in the presence of a
cell-permeable SHP2 inhibitor II-B08 (Fig. 3b). Moreover, the
interaction between Ras and SHP2 was negligible in Src/Yes/Fyn
(SYF)-triple knockout MEFs (Fig. 3b). Notably, we have shown
previously that EGF treatment fails to promote tyrosyl phos-
phorylation of Ras in SYF / MEFs21. Furthermore, EGF-
induced binding between SHP2 and Ras observed in U87 and
RasB8p3 astrocytes was markedly diminished in the presence of II-
B08 (Fig. 3c,d). These results suggest that SHP2 binding to Ras is
dependent on the preceding Src-mediated phosphorylation of Ras.
We next asked whether Ras activation is dependent on SHP2-
dependent dephosphorylation of Ras. Compared with the WT
SHP2, constitutively active disease-causing Flag-SHP2(E76K)
mutant26 markedly reduced the level of tyrosyl phosphorylated
N-Ras and increased the binding of N-Ras to effector Raf:RBD
and GTP-conjugated agarose beads in HEK293 cells (Fig. 4a and
Supplementary Fig. 5a). Conversely, the expression of catalytically
inactive Flag-SHP2(C459S) mutant as well as endogenous SHP2
knockdown in HEK293 cells was associated with hyper-
phosphorylation of N-Ras and reduced the binding of N-Ras to
Raf:RBD and GTP-conjugated beads (Fig. 4a and Supplementary
Fig. 5b,c). The enhanced level of tyrosyl phosphorylated ectopic
or endogenous Ras in the presence of catalytically inactive Flag-
SHP2(C459S) was also associated with reduced level of
phosphorylated ERK, whereas the reduced level of tyrosyl
phosphorylated Ras in the presence of constitutively active
Flag-SHP2(E76K) was associated with increased level of
phosphorylated ERK (Fig. 4a,b). Notably, the effect of
SHP2(WT or E76K or C459S) on N-Ras binding to Raf:RBD
was markedly muted in the presence of kinase-dead c-Src(K295R
Y527F) mutant (Fig. 4c), which supports the notion that
SHP2 regulates the activity of Ras via dephosphorylation of
Src-phosphorylated Ras.
Notably, SHP2 inhibitor II-B08 treatment or ectopic expression
of a dominant-negative Flag-SHP2(C459S) markedly enhanced
phosphorylation of oncogenic HA-N-Ras(12D) mutant, conco-
mitant with reduced binding to Raf:RBD and GTP-loaded beads
and attenuated induction of EGF-induced phosphorylated ERK
level (Fig. 4d and Supplementary Fig. 6). These results suggest
that pharmacologic manipulation of SHP2 activity could
inﬂuence the oncogenic potential of cancer-causing Ras mutants.
In support of this notion, II-B08 treatment attenuated the
elevated SHP2 activity and phosphorylation level observed in
RasB8p3 astrocytes and enhanced tyrosyl phosphorylation of
Flag-SHP2(WT)
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Figure 3 | SHP2 binds to tyrosyl phosphorylated Ras in the presence of
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immunoprecipitated with anti-Flag antibody and immunoblotted with the
indicated antibodies. (b) Wild-type MEFs or Src/Yes/Fyn triple-knockout
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extract.
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Figure 4 | SHP2 inhibition promotes tyrosyl phosphorylation of wild-type and oncogenic Ras leading to inactivation of Ras and downstream signalling.
(a) HEK293 cells transfected with the indicated plasmids were lysed, immunoprecipitated with anti-HA antibody or were pulled down using Raf:RBD beads or
GTP beads, and immunoblotted with the indicated antibodies. (b) HEK293 cells transfected with the indicated plasmids were lysed, immunoprecipitated with
anti-Ras antibody and immunoblotted with the indicated antibodies. (c) HEK293 cells transfected with the indicated plasmids were lysed, pulled down using
Raf:RBD and immunoblotted with the indicated antibodies. (d) HEK293 cells transfected with the indicated plasmids were lysed, immunoprecipitated with anti-
HA antibody or were pulled down using Raf:RBD beads or GTP beads, and immunoblotted with the indicated antibodies. (e) RasB8p3 astrocytes expressing the
HA-H-Ras(12V) transgene were serum starved and pretreated with (þ ) or without ( ) II-B08 followed by treatment with (þ ) or without ( ) 1 ngml 1 of
EGF, lysed, pulled down using Raf:RBD beads and immunoblotted with indicated antibodies. (f) Equal number of RasB8p3 astrocytes were plated in 96-well plates
in sextuplicate and treated with or without (dimethylsulphoxide (DMSO)) increasing concentration of II-B08 for 18 h and alamar blue assay was conducted
according to the manufacturer’s instructions. Data represent mean±s.e.m. of three independent experiments performed in sextuplicates. *Po0.05 Student’s
t-test compared with DMSO control. (g) Equal number of RasB8 astrocytes were suspended in agar matrix, and treated with or without increasing concentrations
of II-B08. Following 10 days incubation, the anchorage-independent growth assay was performed according to the manufacturer’s instructions. Data represent
mean±s.e.m. of three independent experiments performed in sextuplicates. *Po0.05 Student’s t-test compared with DMSO control. Representative images are
also shown on the left panel captured using a Nikon Coolpix 995 digital camera mounted on a VWR Vista Vision inverted microscope. Scale bar, 200mm. The
immunoblot data are representative of at least three separate experiments. IP, immunoprecipitation; PD, pull down; WCE, whole-cell extract.
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oncogenic HA-H-Ras(12V) following EGF treatment (Fig. 2b and
Supplementary Fig. 2b). In addition, II-B08 treatment markedly
suppressed the EGF-induced interaction between H-Ras(12V)
and effector Raf:RBD and concomitantly decreased the level of
phosphorylated ERK, cellular proliferation and growth of
RasB8p3 astrocytes in soft agar (Fig. 4e–g, respectively). We took
advantage of a spontaneous transgenic mouse model of human
glioma, the RasB8 mouse model25, which is a model that forms
low-grade gliomas that progress to a higher-grade glioma with
malignant histopathological and molecular features in keeping
with a GBM. Treatment of these mice with the Il-B08 drug results
in decreased levels of phosphorylated SHP2 and phosphorylated
ERK and a distinct lack of progression of the low-grade tumours
to high-grade gliomas, as evidenced by a reduction in cellularity
as determined by a decrease in nuclei and decrease in
proliferation of astrocytic cells as determined on haematoxylin
and eosin and astrocyte-speciﬁc marker glial ﬁbrillary acidic
protein (GFAP) (Supplementary Fig. 7).
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Consistent with the aforementioned RasB8p3 data, II-B08
treatment decreased the level of phosphorylated SHP2 and
markedly attenuated the EGF-stimulated binding of Ras to
Raf:RBD and phosphorylated level of ERK in a dose-dependent
manner in U87 and U87-viii GBM cells, which harbour
hyperactive, but otherwise WT, Ras (Fig. 5a and Supplementary
Fig. 8). In addition, we showed previously that Ras is
phosphorylated via Src on Y32 within the switch I region, which
is critical for RasGTPase activity21. II-B08 treatment markedly
reduced ERK phosphorylation, cellular viability and proliferation
of U87 astrocytes expressing Flag-N-Ras(WT) but not of Flag-N-
Ras(Y32F) phosphorylation-defective mutant expressing cells
(Fig. 5b–d). Furthermore, ectopic expression of a dominant-
negative Flag-SHP2(C459S) mutant markedly reduced Ras
binding to Raf:RBD beads and attenuated phosphorylated ERK
levels in Flag-N-Ras(WT)-expressing HEK293 cells, but had
negligible effect on HEK293 cells expressing Flag-N-Ras(Y32F)
mutant (Supplementary Fig. 9a). These results support the notion
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Figure 5 | U87 xenograft mice treated with II-B08 demonstrate reduced tumour burden. (a) U87 astrocytes were serum starved and pretreated with
(þ ) or without ( ) increasing concentrations of II-B08 followed by treatment with (þ ) or without ( ) EGF lysed and a pull down (PD) assay was
conducted using Raf:RBD beads. (b) U87 astrocytes transfected with the indicated plasmids were treated with or without (dimethylsulphoxide (DMSO))
increasing concentration of II-B08 for 18 h, lysed and immunoblotted with the indicated antibodies. Equal number of U87 astrocytes transfected with
indicated plasmids were plated in 96-well plates in sextuplicate, treated with or without (DMSO) increasing concentration of II-B08 for 18 h, and alamar
blue (c) or 5-bromodeoxyuridine (BrdU; d) assay was then performed. Data represent mean±s.e.m. of three independent experiments performed in
sextuplicates. *Po0.05 Student’s t-test compared with DMSO control. (e) Equal number of U87 or U87 astrocytes stably expressing EGFRviii deletion
mutant (U87-viii) were plated in 96-well plates in sextuplicate, treated with or without (DMSO) increasing concentration of II-B08 for 18 h, alamar blue
assay was performed. Data represent mean±s.e.m. of three independent experiments performed in sextuplicates. *Po0.05 Student’s t-test compared with
DMSO control. (f) Equal number of U87 or U87-viii astrocytes were suspended in agar matrix and treated with or without increasing concentrations
of II-B08. Following 10 days incubation, the anchorage-independent growth assay was performed. Data represent mean±s.e.m. of three independent
experiments performed in sextuplicates. *Po0.05 Student’s t-test compared with DMSO control. Representative images are shown on top panel captured
using a Nikon Coolpix 995 digital camera mounted on a VWR Vista Vision inverted microscope. Scale bar, 200mm. (g) T2 weighted anatomy MRI imaging
demonstrated reduced tumour appearance after 7 days of therapy, which when quantiﬁed demonstrates a very signiﬁcant decrease in the tumour
volumetrics when compared with placebo (DMSO)-treated control mice following delayed therapy, beginning at 14 days post injection (**P¼0.0053,
Student’s t-test) and immediate therapy, beginning at the day of injection (**P¼0.0059, Student’s t-test). Eight- to ten-week-old mice were used with
n¼ 11 for delayed treatment group, n¼ 7 for delayed control group, n¼9 for immediate treatment group and n¼ 7 for immediate control group. Scale bar,
2mm. (h) Right hemisphere containing the tumour was lysed from mouse treated with or without II-B08 and immunoprecipitated with anti-Ras or control
IgG antibody and immunoblotted using the indicated antibodies. (i) Immunohistochemical staining of U87 tumour tissue following immediate and delayed
Il-B08 treatments conﬁrms a reduction in SHP2 and Ki67, whereas TdT-mediated dUTP nick end labelling (TUNEL), an apoptotic indicator, remained similar.
Images are representative from untreated or immediate or delayed treated mice with II-B08. (j) Quantiﬁcation of Ki67 as a % of total cells in the ﬁeld
demonstrates a statistically signiﬁcant reduction following both treatments (***Po0.0001 ANOVA-post-Tukey). (k) Kaplan–Meier survival curve was
plotted for control, immediate and delayed Il-B08-treated mice. The immunoblot data are representative of at least three separate experiments. IP,
immunoprecipitation; WCE, whole-cell extract.
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that SHP2 inhibition on proliferative signalling depends, at least
in part, on the regulation of Ras phosphorylation status.
Mice treated with II-B08 demonstrate reduced tumour burden.
II-B08 treatment signiﬁcantly reduced cellular proliferation and
anchorage-independent growth of U87 and U87-viii astrocytes in
a dose-dependent manner (Fig. 5e,f). U87-bearing xenograft mice
when exposed to II-B08 demonstrated a signiﬁcant reduction in
overall tumour size 7 days after therapy was started when com-
pared with those treated with placebo. This was demonstrated
using T2weightd MRI imaging in both an immediate therapy
group, beginning at the time of injection (**P¼ 0.0059, Student’s
t-test), as well as in a delayed therapy group, beginning 14 days
after injection (**P¼ 0.0053; Fig. 5g). In comparison to U87
tumour-bearing brain isolated from untreated mice, Ras pre-
cipitated from II-B08-treated brain tissue showed markedly
higher level of tyrosyl phosphorylated Ras concomitant with
reduced level of phosphorylated SHP2 and downstream phos-
phorylated ERK and AKT (Fig. 5h). Immunohistochemical
staining of tissue from the three groups conﬁrmed smaller
tumours in the treated mice, particularly the immediate group.
Treated tumours had reduced SHP2 and Ki67, suggesting that
treatment with II-B08 reduces the proliferative nature of the
tumours and their overall growth (Fig. 5i). The reduction in
proliferation is statistically signiﬁcant in both the delayed and
immediate treatment group (***Po0.0001, analysis of variance
followed by post-Tukey; Fig. 5j). The reduced proliferative nature
of the tumour is consistent with the observed trend of increased
survival at 60 days in immediate and delayed II-B08 treatment
groups in comparison to the placebo-treated control group
(Fig. 5k).
Discussion
SHP2 is the ﬁrst identiﬁed proto-oncogene encoding a cytoplas-
mic tyrosine phosphatase that promotes the activation of the Ras/
ERK/MAPK pathway in response to growth factors, cytokines
and hormones27–29. SHP2 contains the obligatory protein
tyrosine phosphatase domain, two tandem Src homology 2
(SH2) domains and several tyrosine residues that are targeted for
phosphorylation. SH2 domains are necessary for SHP2
engagement on phosphotyrosine in a variety of growth factor
receptors and signalling molecules29. However, although several
mechanisms have been proposed, how SHP2 precisely regulates
Ras/ERK/MAPK pathway is unclear. We recently showed that Src
kinase binds to and preferentially tyrosyl-phosphorylates GTP-
loaded Ras on tyrosine at position 32 within the switch I region;
an event that is associated with Raf displacement while increasing
GAP binding and GTP hydrolysis21. Here, we show that tyrosyl-
phosphorylated Ras binds to and is dephosphorylated by SHP2,
which in turn promotes Ras binding to Raf and the activation of
downstream Ras/ERK/MAPK signalling. These results support
the notion that SHP2 reactivates the inactive tyrosyl-
phosphorylated Ras via dephosphorylation to begin a new Ras
GTPase cycle.
An efﬁcient SHP2 substrate generally contains two or more
acidic residues on the N-terminal side and one or more acidic
residues on the C-terminal side of phosphorylated tyrosine (pY)
with no basic residues30. SHP2 also prefers the acidic residue
aspartic acid (D) at pY  2 position. The sequence surrounding
Ras-pY32, FVDEpY(32)DPTIED, is consistent with the general
SHP2-binding consensus motif. Notably, co-operation between
c-Src-mediated tyrosyl phosphorylation of a target protein and
subsequent dephosphorylation by SHP2 has been shown recently
for the transcription factor RUNX1. Similar to our ﬁndings,
Src-mediated tyrosyl phosphorylation of RUNX1 negatively
affected RUNX1 activity, whereas SHP2-dependent dephospho-
rylation of RUNX1 rescued the negative regulation via Src31. It is
formally unknown whether SHP2-dependent dephosphorylation
of other signalling molecules such as Alpha7 neuronal nicotinic
acetylcholine receptors would rescue the negative effect of
phosphorylation induced by Src family kinases32.
SHP2 has both phosphatase-dependent and -independent
functions via its ability to bind to various signalling molecules33.
For example, it is well established that tyrosyl phosphorylated
SHP2 binds to the adapter Grb2 (ref. 34). Grb2 binds to the
guanine nucleotide exchange factor Son of Sevenless (SOS), which
promotes the removal of GDP from Ras for GTP, a necessary step
in the re-activation of Ras35. We postulate that following SHP2
binding and dephosphorylation of Ras, which requires SHP2’s
phosphatase function, SHP2 via its adapter function recruits
Grb2/SOS complex directly onto Ras to promote Ras activation
and subsequent Raf engagement. Although formally unknown, it
is thus likely that SHP2-mediated activation of Ras/MAPK
signalling requires both SHP2 phosphatase activity as well as its
adapter function.
SHP2 phosphatase function has also been shown to inhibit
recruitment of RasGAPs to the cell membrane36. We recently
showed that tyrosyl phosphorylation of Ras promotes binding to
RasGAP and GTP hydrolysis21. Thus, SHP2-dependent Ras
dephosphorylation would hinder RasGAP binding to Ras or the
recruitment to the cell membrane as noted above; both of which
would increase or prolong Ras activation. SHP2 has also been
shown to dephosphorylate the negative Ras regulator Sprouty to
activate the Ras/ERK/MAPK signalling pathway in the presence
of WT37 but not oncogenic Ras38. However, we show here that
the catalytically inactive SHP2 mutant attenuates oncogenic Ras
activation, which questions the involvement of Sprouty in SHP2-
mediated regulation of Ras. Moreover, Sprouty has also been
shown to negatively or positively regulate RTK signalling
depending on interacting partners and cell context39. SHP2 has
been suggested to activate Ras/MAPK signalling via the activation
of Src40. However, Src on its own does not fully activate but
rather partially contributes to the activation of Ras/MAPK
signalling by phosphorylating Raf alongside other serine
threonine kinases41. We show here that pharmacological or
molecular inhibition of SHP2 phosphatase function does
not lead to the inactivation of Src, but rather promotes Ras
phosphorylation in the presence of catalytically active Src.
Gain-of-function mutations in the SHP2 gene, PTPN11, have
been identiﬁed in Noonan Syndrome42, haematological
malignancies43–47 and other types of cancers, including breast
cancer48, lung cancer, neuroblastoma, pilocytic astrocytoma and
medulloblastoma49–54. According to the Cancer Genome Atlas
database, B2% of GBM patients harbour PTPN11 mutations55.
Despite the rarity of PTPN11 mutations in gliomas53,56, other
components of the Ras signalling pathway, such EGFR, NF-1 and
Ras, are genetically altered or deregulated in the majority of
GBM57. Here, we revealed the molecular mechanism by which
SHP2 regulates Ras activity and show that elevated SHP2 activity
drives GBM progression via Ras activation. Inhibiting SHP2
activity with II-B08 led to the inactivation of this difﬁcult to target
oncogene by promoting its phosphorylation and inhibiting Raf
binding. As Ras transduces signals from many different receptor
tyrosine kinases that are known to be overexpressed in GBM,
including EGFR, FGFR and PDGFR, targeting SHP2 may prove
more effective in GBM, which respond poorly to kinase inhibitor
monotherapy.
We tested the impact of inhibiting SHP2 in a tumour model
where Ras activity is relevant. We took advantage of a
spontaneous transgenic RasB8 mouse model of malignant glioma,
in addition to using orthotopic intracranial xenograft models.
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Following SHP2 inhibition with the administration of II-B08,
there was a clear prevent of progression to higher-grade gliomas,
with histopathological features of malignant gliomas not evident
in the treated animals. In addition, there were reduced levels of
Ki67 proliferation and an overall reduction in tumour cell density
as determined by nuclei in the haematoxylin and eosin-stained
tissues. Given the diffuse and random nature of the gliomas that
form in these mice, measuring overall volume is not an accurate
or meaningful end point. To determine whether SHP2 inhibition
results in decrease tumour growth, we used an orthotopic model
of malignant glioma by injecting malignant human glioma U87
cells intracranially in NOD/SCID mice. When compared with
control mice, SHP2 inhibition resulted in a reduction in tumour
growth and decreased Ki67 proliferation, which were associated
with increased survival of II-B08-treated mice at 60 days post
implantation of malignant U87 glioma cells.
As conﬁrmed by the in vitro work, the inhibition of SHP2 is
able to perturb the RasB8 signalling pathways resulting in
elevated levels of Ras in its phosphorylated state. Phosphorylated
Ras has a lower afﬁnity for its effector Raf that in turn leads to a
reduction in activated downstream proliferative MAPK/ERK
signalling. Overactive Ras levels are a common precursor in both
secondary and primary GBMs and most notably there is an
increase in overactive aberrant Ras in high-grade gliomas when
compared with both low-grade and normal brain. Furthermore,
SHP2 has been shown to be an important player in the classical
subgroup of GBM but not in other less tumourigenic subgroups
as deﬁned by the Cancer Genome Atlas. SHP2 also mediates
PDGFRa-induced gliomagenesis and tumour invasion58,59 and
contributes to EGFRviii-induced cell transformation and tumour
growth22,60. It is therefore plausible that targeting Ras signalling
via the inhibition of SHP2 would attenuate the growth of gliomas
in humans and, perhaps equally important, block the progression
of lower grade gliomas to a higher grade.
Methods
Cells. HEK293, MEF, MEF-SYF( / ) and U87, U251, U118, A172 and T98G
were obtained from American Type Culture Collection. NHA, U87-vIII cell line, an
EGFRviii expression derivative of U87, RasB8 p0 and p3 cells were generated as
previously described25. HEK293-shSHP2 cells were generated using transduction-
ready SHP2 or control non-targeting short hairpin RNA lentiviral particles
according to the manufacturer’s instructions (Santa Cruz Biotechnology) and
stably expressing cells were isolated by puromycin selection. GSCs were derived
from freshly operated tumour samples from GBM patients at the University of
Texas MD Anderson Cancer Center as per guidelines set by institutional review
board guidelines. Each patient provided written informed consent for tumour
tissues and this study was conducted under protocol LAB03-0687, which was
approved by the institutional review board of the University of Texas M. D.
Anderson Cancer Center as described previously61. HEK293, MEF and MEF-
SYF( / ) cells as well as U87, U87-viii, NHA, U251, U118, A172, T98G, RasB8
p(0) and p(3) cells were maintained in DMEM (Invitrogen) supplemented with
10% heat-inactivated fetal bovine serum (Wisent) at 37 C in a humidiﬁed 5% CO2
atmosphere. GSCs were maintained as neurospheres in deﬁned DMEM/F12 media
in the presence of growth factors EGF (20 ngml 1), recombinant basic ﬁbroblast
growth factor (bFGF) (20 ngml 1; R&D systems) and B27 growth supplement
with vitamin A (1:50 working concentration; Life Technologies).
Plasmids and monobodies. Plasmids encoding human pCGN-HA-N-Ras(WT or
12D), pCMV5-c-Src(WT or K295R) and pCMV5-SHP2(WT) were obtained from
Addgene. Flag-SHP2 constructs were obtained from Addgene and subcloned into
pcDNA3. Plasmids were veriﬁed by direct DNA sequencing. Monobodies directed
against SHP2 were generated as previously described24 and generously provided by
Dr Shohei Koide.
Xenograft models of GBM. All animal procedures were carried out according to
animal user protocols approved ethically by the Institutional Animal Care Com-
mittee under the guidelines of the Canadian Council on Animal Care and the
University Health Network Research Ethics Board. Chimeric BM mice (male 8
weeks) were anaesthetized using 0.5mg g 1 of intraperitoneal injection of
20mgml 1 Avertin (Sigma-Aldrich) and 5mg kg 1 of the pre-surgical analgesic
Anafen 1mgml 1 (Ketoprofen) was administered subcutaneously. TearGel
(Novartis) was applied to the eyes to prevent corneal dehydration and abrasion.
Once a toe pinch no longer elicited a response, the scalp was cleaned and hair
removed, and a midline incision was made from the ears to the eyes. Underlying
periosteium was frozen with 2% Lidocaine (Bimeda MTC) and removed with
scissors. Mice were placed on a digital stereotaxic frame and from bregma the
cortex coordinates were identiﬁed (X:1.6, Y:1, Z:0.6). A high-speed dental drill with
a 0.7-mm adaptor (Fine Science Tools) was used to bore a whole through the skull.
2 105 U87 cells resuspended in 10 ml of sterile 1 PBS were injected 3mm deep
through the hole using a 10-ml 30-G Hamilton microsyringe, over a 1-min time
period. Control mice were sham injected. Mice were sutured and returned to a
fresh sterile heated cage to recover and supplemented with 0.3mgml 1 Enro-
ﬂoxacin in the drinking water (Baytril Bayer/CDMV, cat. no.102207).
Transgenic mouse models. GBM transgenic mouse model, RasB8, was generated
through integration of a V12 RasB8 mutation under the control of GFAP-promoter
leaving mice predisposed to sporadic GBM-like astrocytoma25. Embryonic stem
cell complementation methodology was used to integrate a V12 RasB8 mutation
(IRES LACz) under the control of GFAP-promoter into an ICR background strain
mouse. The positive RasB8 male mice are bred heterozygously to ICR females, as
the homozygous crosses are lethal before P14 (ref. 25). Genotyping is carried out
for both the RasB8 mutation and the LACz reporter construct; in addition, LACz
immunohistochemistry (IHC) is carried out to ensure full protein translation.
MRI. A 7-Tesla Bruker model BioSpec 70/30 MR system with B-GA12 gradient
coil, 7.2 cm diameter linear radiofrequency transmitter coil, murine head radio-
frequency receiver coil and murine slider bed was used for serial imaging. Mice
under isoﬂurane anaesthesia were positioned on the MR bed with a bite block and
water warming system to maintain body temperature during imaging. Serial
multiparametric MRI protocol was carried out as previously described62.
Patient-derived tumour samples. Patient resected samples were obtained from
Toronto Western Brain Tumour Bank and processed in accordance with a Uni-
versity Health Network Research Ethics Board-approved protocol.
Antibodies and recombinant proteins. Puriﬁed recombinant GST-H-Ras(WT)
was obtained from Jena Bioscience. Active recombinant human His-c-Src kinase
and GST-SHP2 were obtained from GenWay Biotechnology. Rabbit polyclonal
antibodies against Src, phosphorylated (p)Src(Y416), pAKT, AKT, glutathione
S-transferase (GST), pSHP2(Y542), SHP2 and HA (polyclonal) were obtained from
Cell Signaling Technologies. Polyclonal IgG (sc-2027), pERK (sc-7383), N-Ras
(sc-519), and c-Raf (sc-7267) were obtained from Santa Cruz Biotechnology.
p-c-Raf(Y340) (#44506G) was obtained from Invitrogen. GFAP and Ki67 were
obtained from Dako. Monoclonal antibodies against HA (12CA5) and pTyr (4G10)
(05-321) were obtained from Boehringer Ingelheim and Millipore, respectively.
Monoclonal FLAG-M2 (F1804), b-actin (A5316) (1:10,000), vinculin (V9264)
(1:10,000) and polyclonal ERK (M5670) antibodies (1:5,000) were obtained from
Sigma. All antibodies were utilized at a 1:1,000 dilution unless otherwise speciﬁed.
Chemicals. To prepare SHP2 inhibitor II-B08, the critical intermediate methyl
3-ethynyl-6-hydroxy-1-methyl-2-phenyl-1H-indole-5-carboxylate was prepared
as previously described23 Catalysed by Tetrakis(acetonitrile)copper(I)
hexaﬂuorophosphate in dimethylformamide (DMF), the above intermediate
compound was reacted with N-([1,1’-biphenyl]-4-yl)-3-azidopropanamide and
then hydrolysed to yield II-B08 (two steps yield 64%) in a mixed solvent of
tetrahydrofuran (THF), methanol and 5% LiOH solution (volume ratio: 10:2:3).
PHPS1 was obtained from Millipore. Protein tyrosine phosphatase 1B was obtained
from Calbiochem. PP2 and calyculin A were obtained from Sigma. EGF was
obtained from Invitrogen. Ready to use sodium orthovanadate was obtained from
FIVEphoton Biochemicals. Lambda phosphatase was obtained from New England
Biolabs. Immobilized GTP-agarose was obtained from Jena Bioscience.
Immunoprecipitation and immunoblotting. Immunoprecipitation and western
blotting were performed as described previously63. Cells were harvested in EBC
lysis buffer (50mM Tris, pH 8, 120mM NaCl, 0.5% NP-40) and supplemented
with protease inhibitors (Roche). Lysates were immunoprecipitated using the
indicated antibodies along with protein A-Sepharose (Repligen). In experiments
assessing active Src, cell lysates were incubated with anti-v-Src (Ab-1) mouse (327)
agarose-conjugated antibody (Millipore). Bound proteins were washed ﬁve times in
NETN buffer (20mM Tris, pH 8, 100mM NaCl, 1mM EDTA, 0.5% NP-40), eluted
by boiling in sample buffer and resolved by SDS–polyacrylamide gel
electrophoresis. Proteins were electro-transferred onto polyvinylidene diﬂuoride
membrane (Bio-Rad), blocked and probed with the indicated antibodies. All
uncropped western blots are presented in Supplementary Fig. 10.
Ras activity assay. Ras activity was assessed using the Ras activation assay kit
from Millipore. Brieﬂy, Ras-GTP from various treated lysates was pulled-down
using the GST fusion protein corresponding to human Ras-binding domain
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of Raf-1 bound to agarose. The presence of Ras-GTP was detected by western
blotting using anti-Ras antibody (Millipore).
In vitro kinase and SHP2 dephosphorylation assay. Bacterially puriﬁed
recombinant human GST-H-Ras(WT) was combined with bacterially puriﬁed
recombinant human active His-c-Src kinase in 100 ml of vitro kinase buffer (50mM
HEPES (pH 7.5), 10mM MgCl2, 1mM EGTA, 0.01% Brij-35, 200 mM ATP) 1 h at
room temperature. Thereafter, 1ml of binding buffer was added along with glu-
tathione-Sepharose. Bound proteins were washed ﬁve times in binding buffer and
ﬁnal wash was conducted in SHP2 dephosphorylation buffer and then incubated at
30 C for 30min with increasing amount of recombinant active GST-SHP2 as per
manufacturer’s instructions. Bound proteins were washed ﬁve times in binding
buffer before elution by boiling in sample buffer.
SHP2 activity assay. SHP2 phosphatase activity of treated or untreated cell lysates
with II-B08 was determined using the human/mouse/rat active DuoSet IC kit
(R&D Systems), according to the manufacturer’s instructions. Brieﬂy, the total
cellular SHP2 bound to anti-SHP2 antibody conjugated to agarose beads was
exposed to synthetic phosphopeptide substrate, which is only dephosphorylated by
active SHP2 to generate free phosphate and unphosphorylated peptide. The
amount of free phosphate in the supernatant was determined by a sensitive dye-
binding assay using malachite green and molybdic acid and represents a direct
measurement of SHP2 activity in the cellular system.
Cell proliferation assay. Equal numbers of cells were plated in quadruplicate in
96-well plates in the presence or absence of indicated inhibitors and cellular pro-
liferation was assessed using Alamar Blue proliferation assay as per manufacturer’s
instructions (Invitrogen) or 5-bromodeoxyuridine cell proliferation assay as per
manufacturer’s instructions (BioVision).
Anchorage-independent growth assay. Anchorage-independent transformation
assays were performed using a CytoSelect 96-well cell transformation assay kit (Cell
Biolabs, Inc.). Brieﬂy, equal number of cells were plated in soft agar in a 96-well
plate and cultured in the presence or absence of indicated inhibitors. The trans-
formation was determined according to the protocol provided by the manufacturer.
Immunohistology. Parafﬁn sections of intracranial injected U87 orthotopic
xenografts and RasB8 mice brains were de-parafﬁnated overnight with xylene then
rehydrated through 100, 95, 70% and ddH2O. Antigen pretreatment in low pH
buffer (Vector labs H330) was carried out with boiling under pressure for 3min.
Next endogenous peroxidase was inhibited using 0.3% hydrogen peroxide in
methanol for 20min. 10% serum derived from the secondary antibody source was
used to block for 30min. Sections were incubated for 1 h at room temperature with
indicated primary antibodies. Biotinylated secondary antibodies (Vector Labs) were
next applied for 1 h at room temperature. IHC stains underwent a 30-min
horseradish peroxidase-conjugated ultrastreptavidin labelling (ID labs) treatment
and colour was developed using freshly prepared DAB solution (Vector Labs),
slides were lightly counterstained with haematoxylin, dehydrated in alcohols,
cleared in xylene and mounted in Permount (Fisher). For TdT-mediated dUTP
nick end labelling stain, rehydrated slides were placed in ice-cold Alcohol/Acetic
acid mixture (2:1) for 5min then rinsed with PBS. Sections were treated with buffer
A (50mM Tris-HCl, pH 7.5, 50mM MgCl2, 100mM b-Mercaptoethanol, 0.005%
BSA) for 5–10min before being incubated in a biotin nucleotide cocktail at 37 C
for 90min. After washing in PBS, Alkaline Phosphatase Strepavidin Reagent
(Vector Labs, SA-5100) was applied for 30min. Colour was then developed using
freshly prepared DAB before being lightly counterstained with Mayer’s haema-
toxylin and mounted with Permount.
Image analysis. For IHC data quantiﬁcation, ten high-powered ﬁelds from
minimum ﬁve samples were blindly analysed using Image-J software. Brieﬂy, RGB
images were split and converted to 8 bit gray-scale images. Threshold levels were
adjusted (45pioo225pi) to mask nuclei, resulting images were converted to
binary for analysis. Particle analysis was completed based upon size restrictions of
8pi2–inﬁnity leaving morphology unspeciﬁed. Intensity thresholds were then
modiﬁed in the same way to account for positively stained cells. MRI images were
analysed as a stack using MiPAV software. Tumour areas were deﬁned as ROI by
three-blinded personnel on each image and a reconstructed volumetric algorithm
was setup to deﬁne total volume. Averages were taken for each sample.
Statistical analysis. All experiments were performed in triplicate with mean and
standard error reported. Analysis of variance) followed by a post-Tukey for pair-
wise comparisons. For direct comparisons, an unpaired Student’s t-test was carried
out. Signiﬁcance was deﬁned as *Po0.05.
References
1. Harvey, J. J. An unidentiﬁed virus which causes the rapid production of
tumours in mice. Nature 204, 1104–1105 (1964).
2. Kirsten, W. H. & Mayer, L. A. Morphologic responses to a murine
erythroblastosis virus. J. Natl Cancer Inst. 39, 311–335 (1967).
3. Cox, A. D. & Der, C. J. Ras history: The saga continues. Small GTPases 1, 2–27
(2010).
4. Barbacid, M. ras genes. Annu. Rev. Biochem. 56, 779–827 (1987).
5. Wennerberg, K., Rossman, K. L. & Der, C. J. The Ras superfamily at a glance.
J. Cell Sci. 118, 843–846 (2005).
6. Campbell, S. L., Khosravi-Far, R., Rossman, K. L., Clark, G. J. & Der, C. J.
Increasing complexity of Ras signaling. Oncogene 17, 1395–1413 (1998).
7. Lowy, D. R. & Willumsen, B. M. Function and regulation of ras. Annu. Rev.
Biochem. 62, 851–891 (1993).
8. Milburn, M. V. et al. Molecular switch for signal transduction: structural
differences between active and inactive forms of protooncogenic ras proteins.
Science 247, 939–945 (1990).
9. Scheffzek, K. et al. The Ras-RasGAP complex: structural basis for
GTPase activation and its loss in oncogenic Ras mutants. Science 277, 333–338
(1997).
10. Adari, H., Lowy, D. R., Willumsen, B. M., Der, C. J. & McCormick, F.
Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras
effector binding domain. Science 240, 518–521 (1988).
11. Mattingly, R. R. Activated Ras as a therapeutic target: constraints on directly
targeting ras isoforms and wild-type versus mutated proteins. ISRN Oncol.
2013, 536529 (2013).
12. DeClue, J. E. et al. Abnormal regulation of mammalian p21ras contributes to
malignant tumor growth in von Recklinghausen (type 1) neuroﬁbromatosis.
Cell 69, 265–273 (1992).
13. Schubbert, S. et al. Functional analysis of leukemia-associated PTPN11
mutations in primary hematopoietic cells. Blood 106, 311–317 (2005).
14. Clark, G. J. & Der, C. J. Aberrant function of the Ras signal transduction
pathway in human breast cancer. Breast Cancer Res. Treat. 35, 133–144 (1995).
15. Guha, A., Feldkamp, M. M., Lau, N., Boss, G. & Pawson, A. Proliferation of
human malignant astrocytomas is dependent on Ras activation. Oncogene 15,
2755–2765 (1997).
16. Louis, D. N., Holland, E. C. & Cairncross, J. G. Glioma classiﬁcation: a
molecular reappraisal. Am. J. Pathol. 159, 779–786 (2001).
17. Kleihues, P. & Ohgaki, H. Primary and secondary glioblastomas: from concept
to clinical diagnosis. Neuro-oncology 1, 44–51 (1999).
18. Holland, E. C. Gliomagenesis: genetic alterations and mouse models. Nat. Rev.
Genet. 2, 120–129 (2001).
19. Jiang, B. H., Aoki, M., Zheng, J. Z., Li, J. & Vogt, P. K. Myogenic signaling of
phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein
kinase B. Proc. Natl Acad. Sci. USA 96, 2077–2081 (1999).
20. Scott, L. M. et al. Shp2 protein tyrosine phosphatase inhibitor activity of
estramustine phosphate and its triterpenoid analogs. Bioorg. Med. Chem. Lett.
21, 730–733 (2011).
21. Bunda, S. et al. Src promotes GTPase activity of Ras via tyrosine 32
phosphorylation. Proc. Natl Acad. Sci. USA 111, E3785–E3794 (2014).
22. Scott, L. M., Lawrence, H. R., Sebti, S. M., Lawrence, N. J. & Wu, J. Targeting
protein tyrosine phosphatases for anticancer drug discovery. Curr. Pharm. Des.
16, 1843–1862 (2010).
23. Zhang, X. et al. Salicylic acid based small molecule inhibitor for the oncogenic
Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).
J. Med. Chem. 53, 2482–2493 (2010).
24. Sha, F. et al. Dissection of the BCR-ABL signaling network using highly speciﬁc
monobody inhibitors to the SHP2 SH2 domains. Proc. Natl Acad. Sci. USA 110,
14924–14929 (2013).
25. Ding, H. et al. Astrocyte-speciﬁc expression of activated p21-ras results in
malignant astrocytoma formation in a transgenic mouse model of human
gliomas. Cancer Res. 61, 3826–3836 (2001).
26. Mohi, M. G. et al. Prognostic, therapeutic, and mechanistic implications of a
mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell 7,
179–191 (2005).
27. Matozaki, T., Murata, Y., Saito, Y., Okazawa, H. & Ohnishi, H. Protein tyrosine
phosphatase SHP-2: a proto-oncogene product that promotes Ras activation.
Cancer Sci. 100, 1786–1793 (2009).
28. Chan, R. J. & Feng, G. S. PTPN11 is the ﬁrst identiﬁed proto-oncogene that
encodes a tyrosine phosphatase. Blood 109, 862–867 (2007).
29. Dance, M., Montagner, A., Salles, J. P., Yart, A. & Raynal, P. The molecular
functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2)
pathway. Cell. Signal. 20, 453–459 (2008).
30. Ren, L. et al. Substrate speciﬁcity of protein tyrosine phosphatases 1B,
RPTPalpha, SHP-1, and SHP-2. Biochemistry 50, 2339–2356 (2011).
31. Huang, H. et al. A Src family kinase-Shp2 axis controls RUNX1 activity in
megakaryocyte and T-lymphocyte differentiation. Genes Dev. 26, 1587–1601
(2012).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9859 ARTICLE
NATURE COMMUNICATIONS | 6:8859 | DOI: 10.1038/ncomms9859 | www.nature.com/naturecommunications 11
32. Charpantier, E. et al. Alpha7 neuronal nicotinic acetylcholine receptors are
negatively regulated by tyrosine phosphorylation and Src-family kinases.
J. Neurosci. 25, 9836–9849 (2005).
33. Huang, W. Q. et al. Structure, function, and pathogenesis of SHP2 in
developmental disorders and tumorigenesis. Curr. Cancer Drug Targets 14,
567–588 (2014).
34. Cunnick, J. M., Dorsey, J. F., Munoz-Antonia, T., Mei, L. & Wu, J. Requirement
of SHP2 binding to Grb2-associated binder-1 for mitogen-activated protein
kinase activation in response to lysophosphatidic acid and epidermal growth
factor. J. Biol. Chem. 275, 13842–13848 (2000).
35. Egan, S. E. et al. Association of Sos Ras exchange protein with Grb2 is
implicated in tyrosine kinase signal transduction and transformation. Nature
363, 45–51 (1993).
36. Montagner, A. et al. A novel role for Gab1 and SHP2 in epidermal growth
factor-induced Ras activation. J. Biol. Chem. 280, 5350–5360 (2005).
37. Hanafusa, H., Torii, S., Yasunaga, T., Matsumoto, K. & Nishida, E. Shp2, an
SH2-containing protein-tyrosine phosphatase, positively regulates receptor
tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor
Sprouty. J. Biol. Chem. 279, 22992–22995 (2004).
38. Lee, S. H., Schloss, D. J., Jarvis, L., Krasnow, M. A. & Swain, J. L. Inhibition of
angiogenesis by a mouse sprouty protein. J. Biol. Chem. 276, 4128–4133 (2001).
39. Li, X., Wheldon, L. & Heath, J. K. Sprouty: a controversial role in receptor
tyrosine kinase signalling pathways. Biochem. Soc. Trans. 31, 1445–1446 (2003).
40. Zhang, S. Q. et al. Shp2 regulates SRC family kinase activity and Ras/Erk
activation by controlling Csk recruitment. Mol. Cell 13, 341–355 (2004).
41. Peyssonnaux, C. & Eychene, A. The Raf/MEK/ERK pathway: new concepts of
activation. Biol. Cell 93, 53–62 (2001).
42. Tartaglia, M. et al. Mutations in PTPN11, encoding the protein tyrosine
phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 29, 465–468 (2001).
43. Loh, M. L. et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in
leukemogenesis. Blood 103, 2325–2331 (2004).
44. Tartaglia, M. et al. Somatic PTPN11 mutations in childhood acute myeloid
leukaemia. Br. J. Haematol. 129, 333–339 (2005).
45. Loh, M. L. et al. PTPN11 mutations in pediatric patients with acute myeloid
leukemia: results from the Children’s Cancer Group. Leukemia 18, 1831–1834
(2004).
46. Tartaglia, M. et al. Somatic mutations in PTPN11 in juvenile myelomonocytic
leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat. Genet.
34, 148–150 (2003).
47. Yamamoto, T. et al. PTPN11, RAS and FLT3 mutations in childhood acute
lymphoblastic leukemia. Leuk. Res. 30, 1085–1089 (2006).
48. Aceto, N. et al. Tyrosine phosphatase SHP2 promotes breast cancer progression
and maintains tumor-initiating cells via activation of key transcription factors
and a positive feedback signaling loop. Nat. Med. 18, 529–537 (2012).
49. Rankin, J., Short, J., Turnpenny, P., Castle, B. & Hanemann, C. O.
Medulloblastoma in a patient with the PTPN11 p.Thr468Met mutation. Am. J.
Med. Genet. A 161A, 2027–2029 (2013).
50. Bentires-Alj, M. et al. Activating mutations of the noonan syndrome-associated
SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous
leukemia. Cancer Res. 64, 8816–8820 (2004).
51. Cotton, J. L. & Williams, R. G. Noonan syndrome and neuroblastoma. Arch.
Pediatr. Adolesc. Med. 149, 1280–1281 (1995).
52. Lopez-Miranda, B., Westra, S. J., Yazdani, S. & Boechat, M. I. Noonan
syndrome associated with neuroblastoma: a case report. Pediatr. Radiol. 27,
324–326 (1997).
53. Martinelli, S. et al. Activating PTPN11 mutations play a minor role in pediatric
and adult solid tumors. Cancer Genet. Cytogenet. 166, 124–129 (2006).
54. Miyamoto, D. et al. Isolation of a distinct class of gain-of-function SHP-2
mutants with oncogenic RAS-like transforming activity from solid tumors.
Oncogene 27, 3508–3515 (2008).
55. Sturla, L. M. et al. Src homology domain-containing phosphatase 2 suppresses
cellular senescence in glioblastoma. Br. J. Cancer 105, 1235–1243 (2011).
56. Janzarik, W. G. et al. Further evidence for a somatic KRAS mutation in a
pilocytic astrocytoma. Neuropediatrics 38, 61–63 (2007).
57. Cancer Genome Atlas Research Network. Comprehensive genomic
characterization deﬁnes human glioblastoma genes and core pathways. Nature
455, 1061–1068 (2008).
58. Liu, K. W. et al. SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA
and INK4A/ARF aberrations in mice and humans. J. Clin. Invest. 121, 905–917
(2011).
59. Feng, H. et al. Dynamin 2 mediates PDGFRalpha-SHP-2-promoted
glioblastoma growth and invasion. Oncogene 31, 2691–2702 (2012).
60. Zhan, Y., Counelis, G. J. & O’Rourke, D. M. The protein tyrosine phosphatase
SHP-2 is required for EGFRvIII oncogenic transformation in human
glioblastoma cells. Exp. Cell Res. 315, 2343–2357 (2009).
61. Wei, J. et al. Glioma-associated cancer-initiating cells induce
immunosuppression. Clinical Cancer Res. 16, 461–473 (2010).
62. Chung, C. et al. Imaging biomarker dynamics in an intracranial murine glioma
study of radiation and antiangiogenic therapy. Int. J. Radiat Oncol. Biol. Phys.
85, 805–812 (2013).
63. Ohh, M. et al. Ubiquitination of hypoxia-inducible factor requires direct
binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2,
423–427 (2000).
Acknowledgements
We thank Dr Shohei Koide for providing SHP2 monobodies. This work was supported
by funds from the Canadian Institutes of Health Research (M.O.) and NIH RO1
CA69202 (Z.-Y.Z.).
Author contributions
S.B. designed, performed and interpreted the experiments, conceptualized the project,
and wrote the manuscript. K.B. designed, performed and interpreted the mouse model
study. P.H. designed, generated and performed experiments using expression plasmids
encoding SHP2 mutants. L.Z. designed and puriﬁed SHP2 inhibitors. A.A. performed
mouse model experiments. Y.K. designed and performed endogenous Ras phosphor-
ylation experiments. B.R. designed and assisted in the interpretation of the phosphor-
ylation-based experiments. Z.-Y.Z. designed the SHP2 inhibitors and interpreted SHP2
inhibitor study. G.Z. designed, interpreted and wrote the mouse model study. M.O.
conceptualized the project, interpreted the data and wrote the manuscript.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Bunda, S. et al. Inhibition of SHP2-mediated dephosphorylation
of Ras suppresses oncogenesis. Nat. Commun. 6:8859 doi: 10.1038/ncomms9859 (2015).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9859
12 NATURE COMMUNICATIONS | 6:8859 |DOI: 10.1038/ncomms9859 | www.nature.com/naturecommunications
